Abstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects

Athel Cornish‐Bowden, David Rasnick, Henry H. Heng, Steven D. Horne, Batoul Y. Abdallah, Guo Liu, Christine J. Ye, Mathew Bloomfield, Mark Vincent, C. Marcelo Aldaz, Jenny Karlsson, Anders Valind, Caroline Jansson, David Gisselsson, Jennifer A. Marshall Graves, Aleksei A. Stepanenko, Svitlana Andreieva, Kateryna Korets, Dmytro Mykytenko, Nataliya Huleyuk, Владимир П. Баклаушев, О. А. Ковалева, В. П. Чехонин, Yegor Vassetzky, Stanislav Avdieiev, Björn Bakker, Aaron Taudt, Mirjam E. Belderbos, David Porubský, Diana C.j. Spierings, Tristan V. de Jong, Nancy Halsema, Hinke G. Kazemier, Karina Hoekstra-Wakker, Allan Bradley, Eveline S.j.m. de Bont, Anke van den Berg, Victor Guryev, Peter M. Lansdorp, Maria Colomé Tatché, Floris Foijer, Thomas Liehr, Nicolaas C. Baudoin, Joshua M. Nicholson, Kimberly Soto, Isabel Quintanilla, Jordi Camps, Daniela Cimini, Milena Dürrbaum, Nick Donnelly, Verena Passerini, Charli Kruse, Bianca Habermann, Zuzana Štorchová, Daniele Mandrioli, Fiorella Belpoggi, Ellen K. Silbergeld, Melissa J. Perry, Rolf I. Skotheim, Marthe Løvf, Bjarne Johannessen, Andreas Hoff, Sen Zhao, Jonas M. SveeStrømme, Anita Sveen, Ragnhild A. Lothe, R. Hehlmann, Astghik Voskanyan, Alice Fabarius, Alfred Böcking, Stefan Biesterfeld, Leonid Berynskyy, C. Börgermann, Rainer Engers, Josef Dietz, Andrew J. Fritz, Neelima Sehgal, Jaromı́ra Večeřová, B. Stojkovicz, Hui Ding, Nigel Page, Coralee E. Tye, Sambit Bhattacharya, Jinhui Xu, Gary S. Stein, Janet L. Stein, Ronald Berezney, Xue Gong, Sarah Grasedieck, Julian Swoboda, Frank G. Rücker, Lars Bullinger, Jonathan R. Pollack, Fani-Marlen Roumelioti, Maria Chiourea, Christina Raftopoulou, Sarantis Gagos, Peter DuesbergMolecular 2017 · DOI

Introduction: The Chromosome-First Paradigm

The 3rd Conference on Aneuploidy and Cancer presented a fundamental challenge to the prevailing "Gene Mutation Theory" of oncology. Rather than viewing cancer as a collection of individual genetic errors, the participating researchers proposed a "chromosome-first" perspective. This view posits that aneuploidy—an abnormal number of chromosomes—is the primary driver of cancer's origin, evolution, and its notorious resistance to treatment. By shifting the focus from isolated genes to the systemic stability of the karyotype, these abstracts outline a new framework for understanding malignancy as a form of rapid, chaotic speciation.

Challenging the Somatic Mutation Theory

For decades, the Somatic Mutation Theory (SMT) has been the dominant paradigm, suggesting that a small number of "driver" mutations in specific oncogenes cause cancer. However, the conference participants argue that SMT fails to account for several critical observations in clinical oncology:

  1. The "Silent" Mutation Paradox: Most single-gene mutations have negligible effects on a cell's overall metabolic flux. Metabolic Control Analysis (MCA) suggests that flux control is shared across many enzymes, meaning a single mutation is often buffered by the cell's robust network.
  2. Therapeutic Failure: Targeted drugs rarely provide long-term cures because cancer cells possess an inherent ability to adapt. This adaptability is better explained by the massive genomic shifts allowed by aneuploidy rather than point mutations.
  3. Karyotypic Individuality: Analysis of over 66,000 cases in the NCI-Mitelman Database reveals that every cancer has a unique set of chromosomal abnormalities. The "gene-first" view struggles to find universal genetic signatures because the disease is defined by its chromosomal heterogeneity.

Methodological Innovations in Aneuploidy Research

The abstracts highlight a diverse array of methodologies designed to quantify and track chromosomal instability (CIN):

  • AneuFinder & Single-Cell Sequencing: These bioinformatics tools allow researchers to quantify intratumor heterogeneity and track how chromosome mis-segregation drives tumor evolution in real-time.
  • DNA-Karyometry: This automated image analysis of Feulgen-stained nuclei offers a way to grade malignancy based on total DNA content. Unlike the subjective visual scales of the Gleason score, DNA-karyometry provides an objective metric for genomic chaos.
  • Fluorescence Lifetime Imaging Microscopy (FLIM): A label-free method used to identify metabolic signatures of specific glioblastoma subpopulations, linking metabolic shifts directly to chromosomal states.
  • Comparative Cytogenetics: By studying unique cases like the transmissible facial tumors in Tasmanian devils, researchers can observe how stable, "parasitic" cancer karyotypes survive across different hosts, mimicking the behavior of a new species.

Key Insights: Cancer as Speciation and the Vicious Cycle

One of the most provocative ideas emerging from the conference is the concept of Cancer as Speciation. Researchers such as Duesberg, Heng, and Vincent propose that carcinogenesis is a form of "de-speciation" or "macro-evolution." In this model, aneuploidy creates a new "parasitic species" with its own stable (but abnormal) karyotype, distinct from the host's original genome.

This process is driven by what is termed the "Vicious Cycle" of Genomic Instability. Aneuploidy is not merely a byproduct of cancer; it is a cause of further instability. Even a single extra chromosome can disrupt the delicate balance of the mitotic machinery, leading to an autocatalyzed progression of genomic chaos. While single-gene changes are usually buffered, aneuploidy alters the dosage of thousands of proteins simultaneously, overwhelming the cell's homeostatic mechanisms and forcing a reversion to primitive, unicellular survival modes (Atavism Theory).

Clinical Results and Predictive Power

The practical implications of the aneuploidy theory are most evident in diagnostic and prognostic outcomes:

  • Superiority of Karyometry: In studies of prostate cancer, DNA-grading demonstrated a 100% sensitivity in predicting disease progression. In the same cohort, the traditional Gleason score achieved only 22.2% sensitivity, highlighting the clinical value of measuring chromosomal content.
  • Metastasis Correlation: Research indicates that the risk of metastasis is directly proportional to the degree of aneuploidy. Near-diploid tumors show low heterogeneity and lower metastatic potential, whereas hyper-triploid tumors are significantly more aggressive.
  • Transcriptome Instability (TIN): A study of 555 colorectal cancer patients identified "transcriptome instability" as a pan-cancer characteristic. This instability is driven by aberrant RNA processing and the creation of chimeric RNA molecules, all stemming from the underlying chromosomal imbalance.

Limitations and the Future of Oncology

Despite the compelling evidence presented, the "aneuploidy-first" view remains a minority perspective in a field heavily invested in gene-sequencing and targeted molecular therapies. Critics often argue that aneuploidy is a consequence, rather than a cause, of initial mutations in DNA repair genes. Furthermore, while tools like DNA-karyometry show immense promise, they require larger-scale clinical validation before they can replace current diagnostic standards.

The conference concludes with a call for a paradigm shift. Future research must move toward "active surveillance" and the development of therapies that target the mechanisms of chromosomal segregation. By treating cancer as a systemic chromosomal disease rather than a collection of gene mutations, the oncology community may finally unlock more effective ways to manage this complex and adaptable disease.

Summary updated

Abstract

Approximately 10-15% of acute myeloid leukemia (AML) cases are categorized as "complex karyotype", defined as having three or more chromosome aberrations in the absence of prognostically-favorable rearrangements (t(8;21), inv(16), and t(15;17)) [1]. Complex karyotype AML is associated with unfavorable prognosis, and molecularly-
BibTeX
@inproceedings{cornishbowden2017abstracts,
  author = {Athel Cornish‐Bowden and Athel Cornish‐Bowden and David Rasnick and Henry H. Heng and Steven D. Horne and Batoul Y. Abdallah and Guo Liu and Christine J. Ye and Mathew Bloomfield and Mark Vincent and C. Marcelo Aldaz and Jenny Karlsson and Anders Valind and Caroline Jansson and David Gisselsson and Jennifer A. Marshall Graves and Aleksei A. Stepanenko and Svitlana Andreieva and Kateryna Korets and Dmytro Mykytenko and Nataliya Huleyuk and Владимир П. Баклаушев and О. А. Ковалева and В. П. Чехонин and Yegor Vassetzky and Stanislav Avdieiev and Björn Bakker and Aaron Taudt and Mirjam E. Belderbos and David Porubský and Diana C.J. Spierings and Tristan V. de Jong and Nancy Halsema and Hinke G. Kazemier and Karina Hoekstra-Wakker and Allan Bradley and Eveline S.J.M. de Bont and Anke van den Berg and Victor Guryev and Peter M. Lansdorp and Maria Colomé Tatché and Floris Foijer and Thomas Liehr and Nicolaas C. Baudoin and Joshua M. Nicholson and Kimberly Soto and Isabel Quintanilla and Jordi Camps and Daniela Cimini and Milena Dürrbaum and Nick Donnelly and Verena Passerini and Charli Kruse and Bianca Habermann and Zuzana Štorchová and Daniele Mandrioli and Fiorella Belpoggi and Ellen K. Silbergeld and Melissa J. Perry and Rolf I. Skotheim and Marthe Løvf and Bjarne Johannessen and Andreas Hoff and Sen Zhao and Jonas M. SveeStrømme and Anita Sveen and Ragnhild A. Lothe and R. Hehlmann and Astghik Voskanyan and Alice Fabarius and Alfred Böcking and Stefan Biesterfeld and Leonid Berynskyy and C. Börgermann and Rainer Engers and Josef Dietz and Andrew J. Fritz and Neelima Sehgal and Jaromı́ra Večeřová and B. Stojkovicz and Hui Ding and Nigel Page and Coralee E. Tye and Sambit Bhattacharya and Jinhui Xu and Gary S. Stein and Janet L. Stein and Ronald Berezney and Xue Gong and Sarah Grasedieck and Julian Swoboda and Frank G. Rücker and Lars Bullinger and Jonathan R. Pollack and Fani-Marlen Roumelioti and Maria Chiourea and Christina Raftopoulou and Sarantis Gagos and Peter Duesberg and Mathew Bloomfield},
  title = {{Abstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects}},
  booktitle = {Molecular},
  year = {2017},
  doi = {10.1186/s13039-017-0320-x},
}
Figure